Patents by Inventor Taiyin Yang

Taiyin Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UNITARY PHARMACEUTICAL DOSAGE FORM
    Publication number: 20170079999
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Terrence C. DAHL, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLIYAI, Taiyin YANG
  • Unitary pharmaceutical dosage form
    Patent number: 9545414
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: January 17, 2017
    Assignee: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLC
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • UNITARY PHARMACEUTICAL DOSAGE FORM
    Publication number: 20150174147
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: March 6, 2015
    Publication date: June 25, 2015
    Inventors: Terrence C. Dahl, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLlYAI, Taiyin YANG
  • Unitary pharmaceutical dosage form
    Patent number: 9018192
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT
    Publication number: 20140370102
    Abstract: This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Terrence C. Dahl, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Method and composition for pharmaceutical product
    Patent number: 8871271
    Abstract: This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: October 28, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT
    Publication number: 20140037732
    Abstract: This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.
    Type: Application
    Filed: July 29, 2013
    Publication date: February 6, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • UNITARY PHARMACEUTICAL DOSAGE FORM
    Publication number: 20140037724
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicant: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLC
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Unitary pharmaceutical dosage form
    Patent number: 8598185
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: December 3, 2013
    Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.
    Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
  • Unitary pharmaceutical dosage form
    Publication number: 20070099902
    Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
    Type: Application
    Filed: June 13, 2006
    Publication date: May 3, 2007
    Inventors: Terrence Dahl, Munir Hussain, Robert Lipper, Robert Jerzewski, Mark Menning, Reza Oliyai, Taiyin Yang
  • Method and composition for pharmaceutical product
    Publication number: 20070077295
    Abstract: This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF.
    Type: Application
    Filed: June 13, 2006
    Publication date: April 5, 2007
    Inventors: Terrence Dahl, Mark Menning, Reza Oliyai, Taiyin Yang